Senhwa Biosciences, Inc. (TPEX:6492)
Taiwan flag Taiwan · Delayed Price · Currency is TWD
29.70
-0.15 (-0.50%)
Nov 13, 2026, 1:24 PM CST

Senhwa Biosciences Financials Overview

Millions TWD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
0.961.071110.55
Revenue Growth
-11.11%7.00%0%0%81.82%-10.86%
Gross Profit
0.450.520.480.550.510.32
Operating Income
-323.88-278.26-306.19-311.11-356.12-346.32
Net Income
-315.41-264.77-293.75-296.31-349.63-329.26
Earnings Per Share
-3.43-2.97-3.29-3.32-3.92-3.67
EPS Growth
------

Cash & Debt

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
1,378771.781,0261,3191,6192,033
Total Debt
15.4922.12159.616.1615.38
Net Cash (Debt)
1,363749.671,0111,3091,6032,017
Net Cash Growth
70.02%-25.85%-22.78%-18.33%-20.54%-14.14%
Net Cash Per Share
14.808.4011.3414.6817.9722.50

Cash Flow & CapEx

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-262.59-248.46-294.22-294.4-399.97-300.05
Capital Expenditures
-0.96-0.28-1.95-4.61-0.37-0.24
Free Cash Flow
-263.55-248.74-296.17-299-400.34-300.29
Free Cash Flow Growth
------

Margins

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
46.35%48.60%47.70%55.20%50.50%58.73%
Operating Margin
-33737.71%-26005.51%-30619.10%-31111.10%-35611.50%-62966.54%
Pretax Margin
-32715.94%-24620.19%-29246.40%-29504.50%-34826.00%-59699.45%
Profit Margin
-32855.10%-24744.77%-29374.50%-29630.60%-34963.20%-59864.91%
FCF Margin
-27453.44%-23246.45%-29617.30%-29900.10%-40034.00%-54597.64%

Valuation

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingNov '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Forward PE
-10.2310.2310.2310.239.84
PS Ratio
2765.383667.453879.594539.575140.4216962.14